Q3 2025 Healthcare Global Enterprises Ltd Earnings Call Transcript
Key Points
- HealthCare Global Enterprises Ltd (NSE:HCG) reported its highest-ever quarterly revenue of INR559 crores, marking a 19% year-on-year growth.
- The company achieved a 23% growth in PAT and a 15% growth in adjusted EBITDA, indicating strong financial performance.
- The Oncology business, post-MG Hospital Vizag acquisition, grew by 24%, enhancing the company's regional footprint.
- Emerging Centers showed robust performance with a 25% year-on-year growth, with the Kolkata center growing by 40% and the South Mumbai center by 28%.
- The company is focusing on precision oncology and integrating research and academics, positioning itself at the forefront of cancer care innovation.
- The EBITDA margin decreased from 18.5% in Q2 to 16.45% in Q3, primarily due to seasonal factors and reduced operating leverage.
- The South Mumbai center faced challenges in international business due to geopolitical issues, impacting its performance.
- The Milann business continues to face revenue decline, partly due to competition from the original founder's new centers.
- International patient business was affected by geopolitical tensions, particularly with Bangladesh, impacting medical tourism revenue.
- The company anticipates losses from new brownfield centers in Bangalore, which may offset some of the EBITDA margin expansion.
Ladies and gentlemen, good day and welcome to the Q3 and 9-months FY25 earnings conference call of Healthcare Global Enterprises Limited.
This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions, and expectations of the company, as on date of this call. These statements do not guarantee the future performance of the company and may involve risk and uncertainties that are difficult to predict.
(Operator Instructions) Please note that this conference is being recorded.
Now, I hand over the conference to Dr. B S Ajaikumar, Promoter of Healthcare Global Enterprises Limited. Thank you and over to you, sir.
Thank you very much. Good morning to everyone.
As we all know, HCG has been in the news, recently. And most of the news have been in the public, in the last week. I would just like to reiterate, as we know that there has been a change, where CVC has sold its majority of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
